Target intelligence / Profile preview

Elongator acetyltransferase complex subunit 1 (ELP1)

Target
ELP1
Molecular classification
Enzyme (acetyltransferase complex subunit/scaffold), Histone modification (via complex function), Scaffold protein, Other (component of the Elongator multiprotein complex)
01

Overview

Elongator acetyltransferase complex subunit 1 (ELP1) is the largest core subunit and scaffold of the highly conserved, multiprotein Elongator complex, which is essential for tRNA modification, transcriptional regulation, cytoskeletal organization, and neuron development[1][2][3][4]. ELP1 contains multiple WD40 domains and a tetratricopeptide repeat domain, coordinating the assembly and activity of the Elongator complex subunits[1]. Dysfunction of ELP1, due to inherited mutations (e.g., in familial dysautonomia), impairs neuron growth and maintenance by affecting tRNA modification and cytoskeletal dynamics, particularly in the nervous system[2][3][4][5]. No approved drugs currently target ELP1 directly, but it is a disease-modifying gene of major interest in neurogenetic research and a promising, yet challenging, therapeutic target[1][2][4].

Other names
Elongator complex protein 1IKAPIKBKAPIKK complex-associated proteinTOT1IKI3p150DYSFDIkappaB kinase complex-associated proteininhibitor of kappa light polypeptide gene enhancer in B-cells kinase complex-associated protein
02

Mechanism of action

Not directly exploited by approved drugs; possible mechanisms include modulating acetylation or restoring Elongator complex function

03

Biological functions

Transcription regulationtRNA modificationRegulation of cytoskeleton organization and cell motility (notably in neurons)Protein acetylation and post-transcriptional gene regulationSignaling pathway modulation (e.g., JNK-MAPK)
04

Disease associations

Neurodegenerative disease (notably familial dysautonomia)Developmental and neurodevelopmental disordersPotential roles in other disorders involving defective tRNA modification or transcriptional dysregulation
05

Safety considerations

Restoration of ELP1 in the nervous system presents delivery, dosing, and specificity challenges; potential broad effects due to ELP1's central scaffold and regulatory roles
06

Interacting drugs

None directly established as of current evidence; research ongoing
07

Biomarkers

Decreased ELP1 protein expression in familial dysautonomia; aberrant tRNA modifications or splicing patterns may be used as research biomarkers

Beyond the preview

Go deeper on Elongator acetyltransferase complex subunit 1 (ELP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elongator acetyltransferase complex subunit 1 (ELP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call